FDA Brief

Warning letters Drugs

FDA warning letter to

Accupack Midwest, Inc.

High riskIssued Aug 15, 2024Posted Sep 24, 2024Division of Pharmaceutical Quality Operations III

Accupack Midwest, an over-the-counter drug contract manufacturer, lacked adequate water controls and process validation.

What happened

FDA inspected Accupack Midwest's drug manufacturing facility in Cincinnati, Ohio, from February 22 to 27, 2024. FDA found that the company, a contract manufacturer of over-the-counter (OTC) drug products including sunscreens, anti-itch creams, and analgesics, lacked adequate controls and testing for the water used in its products. FDA also found that the company had not validated its manufacturing processes and had not qualified its equipment or water system.

What FDA found

  1. The company lacked adequate specifications and testing for the water used as a component in its drug products, including limits for objectionable microorganisms and tests for total organic carbon and conductivity.

    21 CFR 211.160(b)
  2. The company did not adequately monitor its water system and resampled and retested water after failures without an appropriate investigation.

    21 CFR 211.160(b); 21 CFR 211.192
  3. The company had not validated the manufacturing processes for its OTC drug products.

    21 CFR 211.100(a)
  4. The company had not qualified its drug product manufacturing equipment or its water system.

    21 CFR 211.100(a)

What FDA wants

FDA tells the company to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence, and to provide detailed remediation plans for the water system, process validation, risk assessment, and a CGMP consultant audit.

Who should pay attention

  • brands that use Accupack Midwest as a contract manufacturer
  • companies buying OTC sunscreens, anti-itch creams, or analgesics made at this site
  • quality teams overseeing contract manufacturers' water systems and process validation

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. LeMaitre Vascular, Inc.

    LeMaitre Vascular's Artegraft graft plant in New Jersey drew an FDA warning letter for water, sterilization and recall-reporting failures.

    High risk
  2. Soliteint Kozmetikai KFT

    Hungarian contract maker Soliteint Kozmetikai failed to test OTC pain-relief drugs and ingredients, FDA says; U.S. production halted.

    High risk